Rajaie Namas

Rajaie Namas

Auto-generated profile, based on publicly available information

Rajaie Namas

Cleveland Clinic Abu Dhabi

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 May 2011 in PLOS ONE
Verified
Journal Article
Open access
PDF file
QMQi Mi
Qi Mi
GCGregory Constantine
Gregory Constantine
CZCordelia Ziraldo
Cordelia Ziraldo
ASAlexey Solovyev
Alexey Solovyev
ATAndres Torres
Andres Torres
YVYoram Vodovotz
Yoram Vodovotz
Complex biological processes such as acute inflammation induced by trauma/hemorrhagic shock/ (T/HS) are dynamic and multi-dimensional. We utilized multiplexing cytokine analysis coupled with data-driven modeling to gain a systems perspective into T/HS. Mice were subjected to surgical cannulation trauma (ST) ± hemorrhagic shock (HS; 25 mmHg), and followed for 1, 2, 3, or 4 h in each case. Serum was assayed for 20 cytokines and NO2−/NO3−. These data were analyzed using four data-driven methods (Hierarchical Clustering Analysis [HCA], multivariate analysis [MA], Principal Component Analysis [PCA], and Dynamic Network Analysis [DyNA]). Using HCA, animals subjected to ST vs. ST + HS could be partially segregated based on inflammatory mediator profiles, despite a large overlap. Based on MA, interleukin [IL]-12p40/p70 (IL-12.total), monokine induced by interferon-γ (CXCL-9) [MIG], and IP-10 were the best discriminators between ST and ST/HS. PCA suggested that the inflammatory mediators found in the three main principal components in animals subjected to ST were IL-6, IL-10, and IL-13, while the three principal components in ST + HS included a large number of cytokines including IL-6, IL-10, keratinocyte-derived cytokine (CXCL-1) [KC], and tumor necrosis factor-α [TNF-α]. DyNA suggested that the circulating mediators produced in response to ST were characterized by a high degree of interconnection/complexity at all time points; the response to ST + HS consisted of different central nodes, and exhibited zero network density over the first 2 h with lesser connectivity vs. ST at all time points. DyNA also helped link the conclusions from MA and PCA, in that central nodes consisting of IP-10 and IL-12 were seen in ST, while MIG and IL-6 were central nodes in ST + HS. These studies help elucidate the dynamics of T/HS-induced inflammation, complementing other forms of dynamic mechanistic modeling. These methods should be applicable to the analysis of other complex biological processes.

19 July 2016 in Current Treatment Options in Rheumatology
Verified
Journal Article
Open access
PDF file
AYAmber Young
Amber Young
RNRajaie Namas
Rajaie Namas
CDCarole Dodge
Carole Dodge
DKDinesh Khanna
Dinesh Khanna
Opinion statement Systemic sclerosis (SSc) is an autoimmune disease initially recognized by hand involvement due to characteristic Raynaud’s phenomenon (RP), puffy hands, skin thickening, and contractures resembling claw deformities. SSc contributes to hand impairment through inflammatory arthritis, joint contractures, tendon friction rubs (TFRs), RP, digital ulcers (DU), puffy hands, skin sclerosis, acro-osteolysis, and calcinosis. These manifestations, which often coexist, can contribute to difficulty with occupational activities and activities of daily living (ADL), which can result in impaired quality of life. However, despite this knowledge, most diagnostic and treatment principles in SSc are focused on visceral manifestations due to known associations with morbidity and mortality. Treatment of inflammatory arthritis is symptom based and involves corticosteroids ≤10 mg daily, methotrexate, tumor necrosis factor inhibitors, tocilizumab, and abatacept. Small joint contractures are managed by principles of occupational hand therapy and rarely surgical procedures. TFRs may be treated similar to inflammatory arthritis with corticosteroids. All patients with RP and DU should keep digits covered and warm and avoid vasoconstrictive agents. Pharmacologic management of RP begins with use of calcium channel blockers, but additional agents that may be considered are fluoxetine and phosphodiesterase 5 (PDE5) inhibitors. DU management also involves vasodilators including calcium channel blockers and PDE5 inhibitors; bosentan has also been shown to prevent DU. In patients with severe RP and active DU, intravenous epoprostenol or iloprost can be used and surgical procedures, such as botulinum injections and digital sympathectomies, may be considered. For those with early diffuse cutaneous SSc needing immunosuppression for skin sclerosis, methotrexate or mycophenolate mofetil can be used, but the agent of choice depends on coexisting manifestations, such as inflammatory arthritis and/or lung involvement. Various pharmacologic agents for calcinosis have been considered but are generally ineffective; however, surgical options, including excision of areas of calcinosis, can be considered. Overall management of hand impairment for all patients with SSc should include occupational hand therapy techniques such as range of motion exercises, paraffin wax, and devices to assist in ADL. Thus, treatment options for the various manifestations contributing to hand impairment in SSc are limited and often modestly efficacious at best. Robust studies are needed to address the manifestations of SSc that contribute to hand impairment.

1 June 2012 in Journal of Critical Care
Verified
Journal Article
Closed access
RNRami Namas
Rami Namas
RZRuben Zamora
Ruben Zamora
RNRajaie Namas
Rajaie Namas
GAGary An
Gary An
JDJohn Doyle
John Doyle
YVYoram Vodovotz
Yoram Vodovotz

10 December 2015 in Antioxidants & Redox Signaling
Verified
Journal Article
Closed access
RNRami Namas
Rami Namas
QMQi Mi
Qi Mi
RNRajaie Namas
Rajaie Namas
KAKhalid Almahmoud
Khalid Almahmoud
Akram ZaaqoqAkram Zaaqoq
Akram Zaaqoq
YVYoram Vodovotz
Yoram Vodovotz
Significance: Traumatic injury elicits a complex, dynamic, multi-dimensional inflammatory response that is intertwined with complications such as multiple organ dysfunction and nosocomial infection. The complex interplay between inflammation and physiology in critical illness remains a challenge for translational research, including the extrapolation to human disease from animal models. Recent Advances: Over the past decade, we and others have attempted to decipher the bio-complexity of inflammation in these settings of acute illness, using computational models to improve clinical translation. In silico modeling has been suggested as a computationally-based framework for integrating data derived from basic biology experiments as well as preclinical and clinical studies. Critical Issues: Extensive studies in cells, mice, and human blunt trauma patients have led us to suggest: 1) that while an adequate level of inflammation is required for healing post-trauma, inflammation can be harmful when it becomes self-sustaining via a Damage-Associated Molecular Pattern (DAMP) / Toll-Like Receptor (TLR)-driven, feed-forward circuit; 2) that chemokines play a central regulatory role in driving either self-resolving or self-maintaining inflammation that drives the early activation of both classical innate and more recently-recognized lymphoid pathways; and 3) the presence of multiple thresholds and feedback loops which could significantly affect the propagation of inflammation across multiple body compartments. Future Directions: These insights from data-driven models into the primary drivers and interconnected networks of inflammation have been used to generate mechanistic computational models. Together, these models may be used to gain basic insights as well as serving to help define novel biomarkers and therapeutic targets.

1 November 2016 in Critical Care Medicine
Verified
Journal Article
Closed access
AAAndrew Bs Abboud
Andrew Bs Abboud
RNRami A. Namas
Rami A. Namas
MRMostafa Ramadan
Mostafa Ramadan
QMQi Mi
Qi Mi
KAKhalid Almahmoud
Khalid Almahmoud
YVYoram Vodovotz
Yoram Vodovotz
Objective: Blunt trauma patients may present with similar demographics and injury severity yet differ with regard to survival. We hypothesized that this divergence was due to different trajectories of systemic inflammation and utilized computational analyses to define these differences. Design: Retrospective clinical study and experimental study in mice. Setting: Level 1 trauma center and experimental laboratory. Patients: From a cohort of 493 victims of blunt trauma, we conducted a pairwise, retrospective, case-control study of patients who survived over 24 hours but ultimately died (nonsurvivors; n = 19) and patients who, after ICU admission, went on to be discharged(survivors; n = 19). Interventions: None in patients. Neutralizing anti-interleukin-17A antibody in mice. Measurements and Main Results: Data on systemic inflammatory mediators assessed within the first 24 hours and over 7 days were analyzed with computational modeling to infer dynamic networks of inflammation. Network density among inflammatory mediators in nonsurvivors increased in parallel with organ dysfunction scores over 7 days, suggesting the presence of early, self-sustaining, pathologic inflammation involving high-mobility group protein B1, interleukin-23, and the Th17 pathway. Survivors demonstrated a pattern commensurate with a self-resolving, predominantly lymphoid response, including higher levels of the reparative cytokine interleukin-22. Mice subjected to trauma/hemorrhage exhibited reduced organ damage when treated with anti-interleukin-17A. Conclusions: Variable type 17 immune responses are hallmarks of organ damage, survival, and mortality after blunt trauma and suggest a lymphoid cell–based switch from self-resolving to self-sustaining inflammation.

23 May 2017 in Arthritis Care & Research
Verified
Journal Article
Closed access
PDF file
RNRajaie Namas
Rajaie Namas
DTDonald P. Tashkin
Donald P. Tashkin
DFDaniel E. Furst
Daniel E. Furst
HWHolly Wilhalme
Holly Wilhalme
CTChi‐Hong Tseng
Chi‐Hong Tseng
PGParticipants in the Scleroderma Lung Study I and members of the Scleroderma Lung Study II Research Group
Participants in the Scleroderma Lung Study I and members of the Scleroderma Lung Study II Research Group